US cancer vaccine market outlook 2020

Cancer vaccines could be divided into to two broad categories of prophylactic (preventive) and therapeutic (treatment) segments. In the USA, cancer vaccines belong to both of these groups have been marketed in past few decades.

The US Food and Drug Administration is taking effective measures to offer better medical care to cancer patients. The FDA is willing to try newer modalities due to which pharmaceutical companies are actively engaged for developing them for different malignancies, noted a new report from ResearchandMarkets.

For this reason, cancer vaccines have gained marketing approval in the USA and in clinical trials they have generated significant data. Increasing demand and higher acceptance rates among patients are expected to increase their sales due to which pharmaceutical companies are actively competing to generate more revenues from this segment. In future, the number of clinical trials is expected to increase to develop cancer vaccines for different malignancies. Some of the products are different stages of clinical trials which are expected to be commercialized in US in coming years.